ES2244006T3 - Bioconjugados y administracion de agentes bioactivos. - Google Patents

Bioconjugados y administracion de agentes bioactivos.

Info

Publication number
ES2244006T3
ES2244006T3 ES97939382T ES97939382T ES2244006T3 ES 2244006 T3 ES2244006 T3 ES 2244006T3 ES 97939382 T ES97939382 T ES 97939382T ES 97939382 T ES97939382 T ES 97939382T ES 2244006 T3 ES2244006 T3 ES 2244006T3
Authority
ES
Spain
Prior art keywords
bioconjugate
cobalamin
cells
bioactive agent
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97939382T
Other languages
English (en)
Spanish (es)
Inventor
Charles B. Grissom
Frederick G. West
W. Allen Howard, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Application granted granted Critical
Publication of ES2244006T3 publication Critical patent/ES2244006T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES97939382T 1996-08-27 1997-08-22 Bioconjugados y administracion de agentes bioactivos. Expired - Lifetime ES2244006T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2503696P 1996-08-27 1996-08-27
US2443096P 1996-08-27 1996-08-27
US25036P 1996-08-27
US24430P 1996-08-27

Publications (1)

Publication Number Publication Date
ES2244006T3 true ES2244006T3 (es) 2005-12-01

Family

ID=26698439

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97939382T Expired - Lifetime ES2244006T3 (es) 1996-08-27 1997-08-22 Bioconjugados y administracion de agentes bioactivos.

Country Status (11)

Country Link
US (4) US6315978B1 (enExample)
EP (1) EP1007533B1 (enExample)
JP (1) JP2001501596A (enExample)
AT (1) ATE298344T1 (enExample)
AU (1) AU738431B2 (enExample)
CA (1) CA2264592C (enExample)
DE (1) DE69733618T2 (enExample)
ES (1) ES2244006T3 (enExample)
NZ (1) NZ334870A (enExample)
PT (1) PT1007533E (enExample)
WO (1) WO1998008859A1 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739313A (en) 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
EP1171162A2 (en) * 1999-04-16 2002-01-16 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as antitumor agents
US6806363B1 (en) * 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
MXPA02003772A (es) 1999-10-15 2005-04-28 Mayo Foundation Conjugados de cobalamina, utiles como agentes para obtencion de imagen y como agentes terapeuticos.
US7591995B2 (en) * 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
WO2001028592A1 (en) * 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging agents and as antitumor agents
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6797521B2 (en) 1999-10-26 2004-09-28 University Of Utah Research Foundation Fluorescent cobalamins and uses thereof
DE10012120A1 (de) * 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
AU6972901A (en) * 2000-05-31 2001-12-11 Mayo Foundation Cobalamin compounds useful as cardiovascular agents and as imaging agents
WO2001092288A2 (en) * 2000-05-31 2001-12-06 Mayo Foundation For Medical Education And Research Cobalamin compounds useful as antibiotic agents and as imaging agents
DK1286704T3 (da) 2000-06-02 2014-09-22 Univ Texas Ethylendicystein (EC)-glucose analoge konjugater
EP1754712A3 (en) * 2000-10-25 2009-01-14 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
TWI228512B (en) * 2000-10-25 2005-03-01 Mayo Foundation Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
US6685917B2 (en) * 2000-11-22 2004-02-03 Rxkinetix, Inc. Treatment of mucositis
AU2002306821A1 (en) * 2001-03-22 2002-10-08 The Ohio State University Research Foundation Enzyme-based anti-cancer compositions and methods
US6752986B2 (en) * 2001-05-24 2004-06-22 The Cleveland Clinic Foundation Composition and methods for affecting metallocorrinoid uptake
US20030031627A1 (en) * 2001-07-31 2003-02-13 Mallinckrodt Inc. Internal image antibodies for optical imaging and therapy
EP1435973A4 (en) * 2001-09-28 2007-05-02 Mayo Foundation SIMULTANEOUS ADMINISTRATION OF A TRANSPORT PROTEIN WITH CONJUGATED COBALAMINE FOR THE DISTRIBUTION OF MEDICINAL PRODUCTS
US6679827B2 (en) 2001-10-11 2004-01-20 Robert E. Sandstrom Magnetic field enhancement of tumor treatment
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20040047917A1 (en) * 2002-09-06 2004-03-11 Stephen Wilson Drug delivery and targeting with vitamin B12 conjugates
US7627373B2 (en) 2002-11-30 2009-12-01 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
CA2516453A1 (en) * 2003-02-20 2004-09-02 The Cleveland Clinic Foundation Composition and methods for inhibiting cell survival
US7232805B2 (en) * 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
US7119065B2 (en) * 2003-10-29 2006-10-10 Nagoya Industrial Science Research Institute Metal complex-protein composite and oxidation catalyst
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US7840263B2 (en) * 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7729761B2 (en) * 2004-07-14 2010-06-01 Cardiac Pacemakers, Inc. Method and apparatus for controlled gene or protein delivery
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
WO2006137886A2 (en) * 2004-09-23 2006-12-28 The Regents Of The University Of California Assay for vitamin b12 absorption and method of making labeled vitamin b12
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
BRPI0610419A2 (pt) * 2005-05-17 2012-10-23 Cargill Inc lecitina granular, lisolecitina, processo para produzir lecitina granular, composição granular, processo para produzir uma composição de lecitina granular, produto, e, processos para produzir lisolecitina granular e para produzir uma composição de lisolecitina granular
EP2374480A3 (en) * 2005-08-19 2013-05-01 Endocyte, Inc. Mutli-drug ligand conjugates
US7774057B2 (en) 2005-09-06 2010-08-10 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression for cardiac protection
DK1965787T3 (da) * 2005-11-30 2013-06-03 Endo Pharmaceuticals Inc Behandling af xerostomi med en svovlindeholdende antioxidant
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
AU2008223431B2 (en) 2007-03-05 2013-06-13 Syracuse University A conjugate of insulin and vitamin B12 for oral delivery
NZ580132A (en) 2007-03-14 2012-11-30 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins to vitamins
KR20100021403A (ko) * 2007-03-19 2010-02-24 인플라블록 팔라큐티칼스, 인크. 코발라민 탁산 생체접합체
JP5634862B2 (ja) 2007-05-16 2014-12-03 カーテーベー トゥモーアフォルシュングス ゲゼルシャフト ミット ベシュレンクテル ハフツング 低粘度アントラサイクリン製剤
CN104383553A (zh) 2007-06-25 2015-03-04 恩多塞特公司 含有亲水性间隔区接头的共轭物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US8684898B2 (en) * 2007-10-18 2014-04-01 The Invention Science Fund I Llc Ionizing-radiation-responsive compositions, methods, and systems
US8529426B2 (en) * 2007-10-18 2013-09-10 The Invention Science Fund I Llc Ionizing-radiation-responsive compositions, methods, and systems
US20090104113A1 (en) * 2007-10-18 2009-04-23 Searete Llc Ionizing-radiation-responsive compositions, methods, and systems
US9557635B2 (en) 2007-10-18 2017-01-31 Gearbox, Llc Ionizing-radiation-responsive compositions, methods, and systems
US8168958B2 (en) * 2007-10-18 2012-05-01 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
GB2453860B (en) 2007-10-18 2011-03-16 Searete Llc Ionizing-radiation-responsive compositions,methods and systems
US8227204B2 (en) * 2007-10-18 2012-07-24 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
US8164074B2 (en) * 2007-10-18 2012-04-24 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
US20090169484A1 (en) 2007-12-28 2009-07-02 Ihi Corporation Iron-salen complex
JP2009274962A (ja) * 2008-05-12 2009-11-26 Yoshihiro Ishikawa 鉄サレン錯体、磁性を有する薬剤、薬剤の誘導システム、並びに磁気検出装置
EP2320728A4 (en) * 2008-07-21 2013-03-13 Osiris Therapeutics Inc TAXAN COMPOUNDS FOR THE TREATMENT OF EYE TROUBLE
WO2010058280A1 (ja) * 2008-11-20 2010-05-27 株式会社Ihi 自己磁性金属サレン錯体化合物
US9603940B2 (en) * 2010-04-06 2017-03-28 Ihi Corporation Metal salen complex derivative and process for production thereof
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
KR20140026396A (ko) 2011-03-08 2014-03-05 어섹스 팔마큐티칼스 인코포레이티드 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
JP2015536323A (ja) 2012-10-16 2015-12-21 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 非天然アミノ酸を含む薬物送達結合体および使用方法
EP2968599A4 (en) 2013-03-14 2016-11-09 Albany Molecular Res Inc LIGAND THERAPEUTIC ACID JUGATES AND LINKERS ON SILICON BASE
CN105307663A (zh) * 2013-04-08 2016-02-03 北卡罗来纳大学教堂山分校 光响应化合物
KR102463973B1 (ko) * 2013-05-22 2022-11-07 알닐람 파마슈티칼스 인코포레이티드 ＳＥＲＰＩＮＡ1 ｉＲＮＡ 조성물 및 이의 사용 방법
CN111437395A (zh) * 2013-08-29 2020-07-24 希望之城 细胞穿透缀合物及其使用方法
GR20130100654A (el) * 2013-11-22 2015-06-18 Χρηστος Γκολφινου Ταπεινος Επιφανειακως τροποποιημενα πολλαπλως αποκρινομενα σε ερεθισματα νανο/μικρο-δοχεια ως φορεις φαρμακων για στοχευμενη θεραπεια διαφορων μορφων καρκινου
WO2020113130A1 (en) * 2018-11-29 2020-06-04 The Trustees Of Dartmouth College Tumor targeting vitamin b12 derivatives for x-ray activated chemotherapy
GB202018713D0 (en) 2020-11-27 2021-01-13 Quadram Inst Bioscience Methods and compositions utilising vitamin b12 binding

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758421A (en) * 1985-03-15 1988-07-19 The Board Of Trustees Of The Leland Stanford Junior University Bleomycin conjugates and method
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
WO1989000692A1 (en) 1987-07-15 1989-01-26 The United States Of America, As Represented By Th Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same
US5047227A (en) * 1988-02-08 1991-09-10 Cytogen Corporation Novel and improved antibodies for site specific attachment of compounds
IL93982A0 (en) * 1989-04-03 1991-01-31 Purdue Research Foundation Method for enhancing transmembrane transport of exogenous molecules
US5608046A (en) * 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
EP0698040A4 (en) * 1993-05-20 1999-01-07 Biotech Australia Pty Ltd LHRH ANTAGONISTS
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
CA2187346C (en) * 1994-04-08 2010-06-29 A. Charles Morgan, Jr. Receptor modulating agents and methods relating thereto
US5574018A (en) * 1994-07-29 1996-11-12 Amgen Inc. Conjugates of vitamin B12 and proteins

Also Published As

Publication number Publication date
US6777237B2 (en) 2004-08-17
US6790827B2 (en) 2004-09-14
DE69733618D1 (de) 2005-07-28
NZ334870A (en) 2000-12-22
CA2264592C (en) 2012-02-21
DE69733618T2 (de) 2006-05-11
WO1998008859A1 (en) 1998-03-05
EP1007533B1 (en) 2005-06-22
EP1007533A1 (en) 2000-06-14
AU4148297A (en) 1998-03-19
US20020049154A1 (en) 2002-04-25
PT1007533E (pt) 2005-09-30
JP2001501596A (ja) 2001-02-06
US6776976B2 (en) 2004-08-17
CA2264592A1 (en) 1998-03-05
ATE298344T1 (de) 2005-07-15
EP1007533A4 (en) 2002-08-07
US20020115595A1 (en) 2002-08-22
US6315978B1 (en) 2001-11-13
US20020111294A1 (en) 2002-08-15
AU738431B2 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
EP1007533B1 (en) Bioconjugates and delivery of bioactive agents
Fu et al. Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting
Nkepang et al. Folate receptor-mediated enhanced and specific delivery of far-red light-activatable prodrugs of combretastatin A-4 to FR-positive tumor
CA2774361C (en) Paa nanoparticles for enhancement of tumor imaging
ES2265047T3 (es) Clorinas sulfonadas como fotosensibilizadores.
Maruani et al. Site-selective multi-porphyrin attachment enables the formation of a next-generation antibody-based photodynamic therapeutic
Zhang et al. Unconventional PROTACs for targeted protein degradation in cancer therapy
He et al. Luminescent AIE dots for anticancer photodynamic therapy
AU2003244843B2 (en) Conjugates of N-hydroxypropymethacrylamide-methacrylate copolymer with nuclide activation agent and/or anti-cancer compounds
Sibrian-Vazquez et al. 10 Boron Tumor Delivery
Shah et al. A Physiochemical, In Vitro, and In Vivo Comparative Analysis of Verteporfin–Lipid Conjugate Formulations: Solid Lipid Nanoparticles and Liposomes
ES2374437T3 (es) Terapia fotodinámica que utiliza quimioluminiscencia y un conjugado ligando-fotosensibilizante.
Yao et al. Platinated porphyrin tailed with folic acid conjugate for cell-targeted photodynamic activity
Wu et al. Hypoxia-responsive theranostic nanoplatform with intensified chemo-photothermal/photodynamic ternary therapy and fluorescence tracing in colorectal cancer ablation
Zhou et al. Advances in the delivery, activation and therapeutics applications of bioorthogonal prodrugs
US8906343B2 (en) PAA nanoplatforms containing fluorophores and targeted moieties covalently linked and photosensitizer post-loaded
Akhter et al. Porphyrin-based nanomaterials for cancer nanotheranostics
ES2929784T3 (es) Complejos de rutenio para el tratamiento del cáncer que comprende células madre cancerosas
EP1309330B1 (en) Photosensitizers with ligand targeting properties for tumor therapy
Welfare Exploration and Expansion of the Photolytic Properties of Cobalamin
Bray Advancing a methodology for implant-triggered cancer treatment with Bioorthogonal Palladium-Labile prodrugs
Sorensen Synthesis and testing of novel porphyrins for use in photodynamic therapy
HK1167303B (en) Paa nanoparticles for enhancement of tumor imaging
Wang et al. A Dual-mechanism Targeted Cross-convergence Prodrug Activation Strategy Enabled by Biological Stimulus Amplification towards Precision Cancer Therapy
Bohl Kullberg Tumor Cell Targeting of Stabilized Liposome Conjugates: Experimental studies using boronated DNA-binding agents